Veru (VERU) Stock News

Veru Inc. (NASDAQ: VERU) has successfully developed a novel modified release oral formulation for enobosarm, a selective androgen receptor modulator targeted for chronic weight loss management. The company completed a single dose, open label pilot study that confirmed the desired pharmacokinetic profile of the new 3mg formulation.

The study demonstrated key improvements including reduced maximum plasma concentration, delayed time to maximum plasma concentration, and a distinct secondary peak plasma concentration, while maintaining similar absorption compared to immediate release capsules. The formulation, developed in partnership with Laxxon Medical using SPID®-Technology, is protected by patents through 2037, with new patent applications potentially extending protection until 2046.

Veru (NASDAQ: VERU) has announced a 1-for-10 reverse stock split effective August 8, 2025, with split-adjusted trading beginning August 11, 2025. The reverse split aims to regain compliance with Nasdaq's $1.00 minimum bid price requirement.

The split, approved by shareholders on July 25, 2025, will consolidate every 10 shares into one share, maintaining the $0.01 par value. No fractional shares will be issued, with cash payments provided instead. The company's transfer agent, Computershare, will manage the exchange process, with shareholders receiving instructions for surrendering pre-split certificates.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company specializing in cardiometabolic and inflammatory disease treatments, will host a conference call and webcast to discuss its fiscal 2025 third quarter financial results on Tuesday, August 12, 2025, at 8:00 a.m. ET.

The event will be accessible via webcast on the company's website at www.verupharma.com. Investors can join by phone at 1-800-341-1602 (domestic) or 1-412-902-6706 (international). A replay will be available online for three months and by phone for one week.

Veru (NASDAQ: VERU), a late clinical stage biopharmaceutical company specializing in cardiometabolic and inflammatory disease treatments, has announced its participation in the 2025 BTIG Virtual Biotech Conference. The company will engage in one-on-one meetings and deliver a fireside chat presentation to investors during the conference, which is scheduled for July 29-30, 2025.

Veru (NASDAQ:VERU) announced positive results from their Phase 2b QUALITY and Maintenance Extension Study for enobosarm, a treatment aimed at preventing weight regain after discontinuing semaglutide (GLP-1 receptor agonist).

The study showed that while the placebo group regained 43% of lost body weight after stopping semaglutide, enobosarm 3mg reduced weight regain by 46% and completely prevented fat regain. The enobosarm groups demonstrated up to 93% greater fat loss and 100% lean mass preservation compared to placebo.

Based on these positive results, Veru will advance enobosarm 3mg to Phase 3 clinical trials and has secured an FDA meeting to discuss the program. The drug showed a favorable safety profile with minimal gastrointestinal side effects during the maintenance period.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company specializing in cardiometabolic and inflammatory disease treatments, has announced its participation in the upcoming virtual BTIG Obesity Health Forum on June 18, 2025. The company will engage in one-on-one meetings with investors and deliver a fireside chat presentation during the event. This forum provides Veru an opportunity to showcase its developments and connect with potential investors in the obesity healthcare sector.

Veru Inc. (NASDAQ: VERU) announced positive safety results from its Phase 2b QUALITY clinical study evaluating enobosarm in combination with semaglutide (Wegovy®) for weight management. The study showed that enobosarm 3mg + semaglutide led to significant improvements: • 99.1% of total weight loss was from fat mass while preserving lean mass • Fewer gastrointestinal side effects compared to semaglutide alone • 62.4% reduction in patients experiencing decline in physical function • No serious treatment-related adverse events Based on these results, Veru will advance the 3mg dose to Phase 3 trials and has requested an End of Phase 2 meeting with FDA expected in Q3 2025. The company is also developing a novel modified release formulation of enobosarm with potential patent protection until 2045.

Veru Inc. (NASDAQ: VERU) has released a Virtual Investor KOL segment featuring obesity expert Louis J. Aronne, MD, FACP. The segment includes a discussion between Dr. Aronne and Veru's President, CEO, and Founder, Mitchell Steiner, M.D., F.A.C.S, focusing on obesity and GLP-1s, current treatment landscape, and unmet needs in the field. The discussion also highlights Veru's lead program, the Enobosarm Phase 2b QUALITY study, and reviews the company's latest topline clinical data.

Veru Inc. (NASDAQ: VERU) reported fiscal Q2 2025 results and clinical progress for its enobosarm program. The company's Phase 2b QUALITY study showed positive results in combining enobosarm with GLP-1 RA drugs, demonstrating significant benefits in fat loss while preserving lean mass. Key findings include a 71% reduction in lean mass loss and improved body composition, with the 3mg dose showing >99% preservation of lean mass. The study revealed that enobosarm + semaglutide resulted in more selective fat loss (90.6%) compared to placebo + semaglutide (68%). Physical function tests showed significant improvements, with a 54.4% reduction in patients experiencing physical decline. Veru expects unblinded safety data and extension study results in Q2 2025, followed by an FDA End of Phase 2 meeting in Q3 2025. The company reported a net loss of $7.9 million ($0.05 per share) for Q2 2025.